Skip to main content
Clinical Trials/JPRN-UMIN000040511
JPRN-UMIN000040511
Completed
未知

Prevalence of HRR-related genes mutations and prognosis in metastatic castration resistant prostate cancer (mCRPC) patients in real world setting(ZENSHIN Study) - Prevalence of HRR-related genes mutations and prognosis in metastatic castration resistant prostate cancer (mCRPC) patients in real world setting(ZENSHIN Study)

AstraZeneca K.K.0 sites155 target enrollmentMay 25, 2020

Overview

Phase
未知
Intervention
Not specified
Conditions
metastatic castration resistant prostate cancer (mCRPC)
Sponsor
AstraZeneca K.K.
Enrollment
155
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 25, 2020
End Date
December 31, 2020
Last Updated
2 years ago
Study Type
Observational
Sex
Male

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. Patients who have failed HRR\-related gene mutation testing with the myChoice HRD plus in screening period. 2\. Patients who have an only FFPE primary tumor sample (primary or metastatic) with unbuffered formalin including acidic formalin. 3\. Patients who have taken an investigational medical product for prostate cancer from Jan 1st , 2014 to Dec 31st 2020\.

Outcomes

Primary Outcomes

Not specified

Similar Trials